Europe Gastrointestinal Therapeutics Market Size & Outlook
Related Markets
Europe gastrointestinal therapeutics market highlights
- The Europe gastrointestinal therapeutics market generated a revenue of USD 12,319.6 million in 2025.
- The market is expected to grow at a CAGR of 1.8% from 2026 to 2033.
- In terms of segment, branded was the largest revenue generating drug type in 2025.
- Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 12,319.6 million |
| Market revenue in 2033 | USD 14,199.2 million |
| Growth rate | 1.8% (CAGR from 2026 to 2033) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.8% of the global gastrointestinal therapeutics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 14,565.1 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastrointestinal Therapeutics Market Scope
Gastrointestinal Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Janssen Pharmaceuticals | View profile | 1-10 | Titusville, New Jersey, United States, North America | https://www.xarelto-us.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Organon & Co Ordinary Shares | View profile | 10000 | 30 Hudson Street, Floor 33, Jersey City, NJ, United States, 07302 | https://www.organon.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
| Abbott Laboratories | View profile | 114000 | 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 | https://www.abbottinvestor.com |
Europe gastrointestinal therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.04% in 2025. Horizon Databook has segmented the Europe gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2021 to 2033.
Europe held the second largest share in the gastrointestinal therapeutics market in 2019. The region is anticipated to experience a steady CAGR over the forecast period, owing to various patent expirations and the subsequent entry of generics in the coming years.
In addition, increasing collaborations between healthcare organizations to enhance awareness and rising availability of varied treatment options can also be attributed to the significant share garnered by the region.
Moreover, regulatory authorities, such as European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA), are consistently working toward ensuring high safety standards for drugs marketed in the region.
Reasons to subscribe to Europe gastrointestinal therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe gastrointestinal therapeutics market databook
-
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe gastrointestinal therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into Europe gastrointestinal therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Europe gastrointestinal therapeutics market size, by country, 2021-2033 (US$M)
Europe Gastrointestinal Therapeutics Market Share, 2025 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
